Additional Ring Containing Patents (Class 544/206)
  • Patent number: 9801381
    Abstract: A crystal form of rimsulfuron is provided that exhibits improved solubility and decreased viscosity. Furthermore, a process for its preparation is provided. The novel crystal form is particularly suitable for use in herbicidal compositions and in the control of unwanted plant growth.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 31, 2017
    Assignee: ROTAM AGROCHEM INTERNATIONAL COMPANY LIMITED
    Inventor: James Timothy Bristow
  • Patent number: 9693558
    Abstract: A crystalline form of mesosulfuron-methyl of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: July 4, 2017
    Assignee: ROTAM AGROCHEM INTERNATIONAL COMPANY LIMITED
    Inventor: James Timothy Bristow
  • Patent number: 9668483
    Abstract: A herbicidal composition is provided, the composition comprising: (A) the crystalline modification I of 2-(4-mesyl-2-nitrobenzoyl)cyclohexane-1,3-dione (mesotrione); and (B) the crystalline modification I of methyl 2-[[[[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)methylamino]carbonyl]amino]sulfonyl]benzoate (tribenuron-methyl). A method of controlling plant growth at a locus comprises applying to the locus herbicidally effective amounts of both (A) the crystalline modification I of 2-(4-mesyl-2-nitrobenzoyl)cyclohexane-1,3-dione (mesotrione); and (B) the crystalline modification I of 2-[[[[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)methylamino]carbonyl]amino]sulfonyl]benzoate (tribenuron-methyl).
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: June 6, 2017
    Assignee: ROTAM AGROCHEM INERNATIONAL COMPANY LIMITED
    Inventor: James Timothy Bristow
  • Patent number: 9668484
    Abstract: A herbicidal composition is provided, the composition comprising: (A) the crystalline modification I of 2-(4-mesyl-2-nitrobenzoyl)cyclohexane-1,3-dione (mesotrione); and (B) the crystalline modification I of 1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-ethylsulfonyl-2-pyridylsulfonyl)urea (rimsulfuron). A method of controlling plant growth at a locus comprises applying to the locus herbicidally effective amounts of both (A) the crystalline modification I of 2-(4-mesyl-2-nitrobenzoyl)cyclohexane-1,3-dione (mesotrione); and (B) the crystalline modification I of 1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-ethylsulfonyl-2-pyridylsulfonyl)urea (rimsulfuron).
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: June 6, 2017
    Assignee: ROTAM AGROCHEM INTERNATIONAL COMPANY LIMITED
    Inventor: James Timothy Bristow
  • Patent number: 9661851
    Abstract: A herbicidal composition is provided, the composition comprising: (A) the crystalline modification I of 2-(4-mesyl-2-nitrobenzoyl)cyclohexane-1,3-dione (mesotrione); and (B) the crystalline modification I of methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-?-(methanesulfonamido)-p-toluate (mesosulfuron-methyl). A method of controlling undesirable plant growth at a locus comprises applying to the locus herbicidally effective amounts of both (A) the crystalline modification I of 2-(4-mesyl-2-nitrobenzoyl)cyclohexane-1,3-dione (mesotrione); and (B) the crystalline modification I of methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-?-(methanesulfonamido)-p-toluate (mesosulfuron-methyl).
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: May 30, 2017
    Assignee: ROTAM AGROCHEM INTERNATIONAL COMPANY LIMITED
    Inventor: James Timothy Bristow
  • Patent number: 9035048
    Abstract: The invention relates to compounds of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with the activity of AMP-activated protein kinase (AMPK). Another object of the invention concerns the use of said compounds for enhancing glucose homeostasis, improving podocytopathy and/or decreasing the production of reactive oxygen species (ROS). The invention also relates to a method for in-vitro diagnosing diabetic nephropathy and a method for screening compounds that reduce podocytopathy, in each case by applying synaptopodin as biomarker.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 19, 2015
    Assignee: POXEL
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Didier Mesangeau, Samer Elbawab
  • Publication number: 20150018328
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Patent number: 8895732
    Abstract: Method for the chromatographic separation of compounds of the formula (I), in which R1, R2, R3, R4, R5, R6 have the meanings indicated in Claim 1, and acid-addition salts thereof, characterized in that the separation is carried out on a chiral ion-exchanger material.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: November 25, 2014
    Assignee: Merck Patent GmbH
    Inventors: Matthias Helmreich, Claus Peter Niesert, Michael Schulte, Wolfgang Lindner, Michael Laemmerhofer, Christian Hoffmann
  • Publication number: 20140341986
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
  • Patent number: 8846911
    Abstract: The present invention discloses a process for isolating enantiomer components from a mixture of enantiomers through particle-size-controlled crystallization, comprising the steps of: (a) forming a solution of a mixture of enantiomers (R) and (S) in a solvent in the absence of any further additives or agents; (b) seeding the solution of step (a) simultaneously or consecutively with seed crystals of enantiomer (R) and with seed crystals of enantiomer (S), wherein the seed crystals of enantiomer (R) differ in size and/or in quantity from the seed crystals of enantiomer (S) to allow separation of the crystals composed of a mixture enriched with enantiomer (R) from the crystals composed of a mixture enriched with enantiomer (S); (c) inducing simultaneous crystallization of enantiomer (R) and enantiomer (S); and (d) isolating crystals composed of a mixture enriched with enantiomer (R) from crystals composed of a mixture enriched with enantiomer (S) through size separation of the crystals, preferably through sieving
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: September 30, 2014
    Assignee: Poxel
    Inventors: David Maillard, Guntram Koller, Ewgenij Wakaresko, Sabine Gottburg-Reininger
  • Patent number: 8742003
    Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: June 3, 2014
    Assignee: BASF SE
    Inventors: Christina Haaf, Markus Hickl, Ruediger Stark, Horst Hintze-Bruening, Bernd Bruchmann, Dirk Schmelter, Thomas Gloege, Christine Roesch
  • Patent number: 8742103
    Abstract: The present invention relates to a new process of separation of triazine derivatives enantiomers involving tartaric acid.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 3, 2014
    Assignee: Poxel
    Inventors: Daniel Cravo, Matthias Helmreich
  • Patent number: 8742102
    Abstract: A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: June 3, 2014
    Assignee: Poxel
    Inventors: Matthias Helmreich, Claus-Peter Niesert, Daniel Cravo, Gérard Coquerel, Guillaume Levilain, Saoussen Wacharine-Antar, Pascal Cardinael
  • Patent number: 8657947
    Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: February 25, 2014
    Assignee: BASF SE
    Inventors: Bastian Noller, Reinhold Schwalm, Christine Roesch, Thomas Breiner, Jean-Francois Stumbe, Christina Haaf
  • Publication number: 20130267705
    Abstract: The present invention describes novel triazines, their related pyrimidines and their use in controlling insects. This invention also includes new synthetic procedures, intermediates for preparing the compounds, pesticide compositions containing the compounds, and methods of controlling insects using the compounds.
    Type: Application
    Filed: July 20, 2011
    Publication date: October 10, 2013
    Applicant: Vestaron Corporation
    Inventors: Robert M. Kennedy, Bruce A. Steinbaugh
  • Publication number: 20130150365
    Abstract: The present invention describes novel triazines, their related pyrimidines and their use in controlling insects. This invention also includes new synthetic procedures, intermediates for preparing the compounds, pesticide compositions containing the compounds, and methods of controlling insects using the compounds.
    Type: Application
    Filed: February 6, 2013
    Publication date: June 13, 2013
    Applicant: Vestaron Corporation
    Inventor: Vestaron Corporation
  • Patent number: 8461331
    Abstract: Process for the preparation of compounds of the formula I in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in claim 1, which comprises the reaction of a compound of the formula II in which R1, R2, R3, R4 have the meanings indicated above, with a compound of the formula III in which R5, R6 have the meanings indicated above.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: June 11, 2013
    Assignee: Poxel SAS
    Inventors: Matthias Helmreich, Mike Brandner
  • Patent number: 8455252
    Abstract: Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant cancer cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can be used to boost the bio-avail-ability of one or more effective cancer killing drugs, making it possible to use certain widely used chemotherapeutic reagent to treat multidrug resistance cancers. Using these compounds in combination with chemotherapeutic drugs that are substrates for ABCG2 and related proteins may also find utility in treating cancer cells that are not currently identified as multi-drug resistant. Additionally, these compounds appear to accelerate the intercellular degradation of ABCG2 and related proteins.
    Type: Grant
    Filed: October 24, 2009
    Date of Patent: June 4, 2013
    Assignee: Indiana University Research and Technology Corp.
    Inventors: Jian-Ting Zhang, Jing Qi, Hui Peng, Zizheng Dong
  • Publication number: 20130000516
    Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.
    Type: Application
    Filed: September 10, 2012
    Publication date: January 3, 2013
    Applicant: BASF SE
    Inventors: Bastian Noller, Reinhold Schwalm, Christine Rösch, Thomas Breiner, Jean-Francois Stumbe, Cristina Haaf
  • Patent number: 8324379
    Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: December 4, 2012
    Assignee: Koronis Pharmaceuticals, Inc.
    Inventors: Richard Daifuku, Alexander Gall, Dmitri Sergueev, Dina Sologub, Kevin Harris
  • Patent number: 8323624
    Abstract: Novel s-triazine sunscreens have the structural formula (I): and are formulated into cosmetic/dermatological photoprotective compositions useful for photoprotecting keratinous substances against the damaging effects of UV-radiation.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: December 4, 2012
    Assignee: L'Oreal
    Inventors: Herve Richard, Catherine Lejuste
  • Patent number: 8221730
    Abstract: UV-photoprotective sunscreen compositions contain at least one novel silanic p-aminobenzalmalonate-substituted s-triazine compound having the general formula (I):
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: July 17, 2012
    Assignee: L'Oreal
    Inventor: Hervé Richard
  • Patent number: 8221728
    Abstract: UV-photoprotective sunscreen compositions contain at least one novel silanic p-aminobenzalmalonate-substituted s-triazine compound having the general formula (I):
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: July 17, 2012
    Assignee: L'Oreal
    Inventor: Herve Richard
  • Publication number: 20120040837
    Abstract: (1,3,5)-Triazinyl phenyl hydrazones are effective at controlling insects.
    Type: Application
    Filed: October 19, 2011
    Publication date: February 16, 2012
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Noormohamed M. Niyaz, Katherine A. Guenthenspberger, Ricky Hunter, Annette V. Brown, Jaime S. Nugent
  • Publication number: 20110263846
    Abstract: UV-photoprotective sunscreen compositions contain at least one novel silanic p-aminobenzalmalonate-substituted s-triazine compound having the general formula (I):
    Type: Application
    Filed: July 8, 2011
    Publication date: October 27, 2011
    Applicant: L'OREAL
    Inventor: Herve RICHARD
  • Publication number: 20110178212
    Abstract: The invention relates to a method for producing at least one compound having at least one at least monosubstituted amino group. According to the invention, a starting substance having at least one amino group is reacted with an alcohol in a reaction mixture in the presence of ammonia.
    Type: Application
    Filed: March 27, 2009
    Publication date: July 21, 2011
    Applicant: BOREALIS AGROLINZ MELAMINE GMBH
    Inventors: Rene Dicke, Andreas Endesfleder, Martin Burger, Christoph Hahn, Clemens Schwarzinger, Wolfgang Fuerst, Harald Schmidt
  • Patent number: 7982034
    Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: July 19, 2011
    Assignee: Koronis Pharmaceuticals, Incorporated
    Inventors: Richard Daifuku, Alexander Gall, Dmitri Sergueev, Dina Sologub, Kevin Harris
  • Publication number: 20110098363
    Abstract: The present invention is directed to chemical compounds of formula (I) wherein A1 is selected from the group consisting of alkyl, aryl, alkylaryl and (formula A), A2, A3, A4, A5 and in case A1 is (formula A) also A6 and A7 comprise a polymer selected from the group consisting of [EO]k[XO]m, [PO]p[EO]q, [EO]k[XO]m[EO]n and [PO]p[EO]q[XO]m with [XO] being [PO] or [BuO] and with EO having the meaning of ethylene oxide, PO having the meaning of propylene oxide and BuO having the meaning of butylene oxide.
    Type: Application
    Filed: May 28, 2009
    Publication date: April 28, 2011
    Applicant: BASF SE
    Inventors: Sebastien Garnier, Marta Reinoso Garcia, Guenter Oetter
  • Publication number: 20100331329
    Abstract: The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.
    Type: Application
    Filed: September 10, 2010
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Elaine Sophie Elizabeth Stokes, Craig Anthony Roberts, Michael James Waring
  • Publication number: 20100305317
    Abstract: Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates Compounds of formula (I) or salts thereof, in which R1, R2, R3, R4, R5, R6, X and Y are defined as in claim 1, can be prepared by a process characterized in that a compound of the formula (II) or a salt thereof, is reacted to a compound of the formula (III) or a salt thereof, and an aluminium (III) source, optionally, in the presence of a protic additive or solvent selected from the group consisting of alcohols or amines. The compounds (I) are suitable to be used for the preparation of heterocyclic compounds corresponding to (I) where the group Al(X)(Y) is replaced with an optionally substituted carbon atom, or s-triazine derivatives thereof.
    Type: Application
    Filed: November 25, 2008
    Publication date: December 2, 2010
    Applicant: Bayer CropScience AG
    Inventor: Mark James Ford
  • Publication number: 20100249137
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof. The compounds of the invention can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension, asthma, and COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: April 9, 2010
    Publication date: September 30, 2010
    Inventors: Yun DING, Reema K. Thalji, Joseph P. Marino, JR.
  • Publication number: 20100210656
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: October 10, 2008
    Publication date: August 19, 2010
    Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, JR.
  • Patent number: 7767676
    Abstract: The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 3, 2010
    Assignee: Merck Sante
    Inventors: Gerard Moinet, Daniel Cravo, Liliane Doare, Micheline Kergoat, Didier Mesangeau
  • Publication number: 20100127616
    Abstract: Disclosed is an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution. Also disclosed is a compound useful for the fabrication of said organic EL device. The organic electroluminescent device comprises organic layers including a light-emitting layer disposed between an anode and a cathode which are piled one upon another on a substrate and at least one of said organic layers comprises a compound for an organic EL device represented by general formula (1). Said organic layer is preferably a light-emitting layer containing a phosphorescent dopant.
    Type: Application
    Filed: March 26, 2008
    Publication date: May 27, 2010
    Applicant: NIPPON STEEL CHEMICAL CO., LTD.
    Inventors: Takahiro Kai, Toshihiro Yamamoto, Masanori Hotta, Junya Ogawa
  • Patent number: 7718655
    Abstract: Trisubstituted triazines can be synthesized from cyanuric chloride. These compounds are useful anti-tubulin agents for treating cancer and proliferative diseases.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: May 18, 2010
    Assignee: New York University
    Inventors: Young-Tae Chang, Alexander Schier, Ho-Sang Moon, Eric Jacobson, Puja Parikh
  • Patent number: 7700605
    Abstract: The invention relates to compounds of the formula I and salts thereof, to a process for their manufacture, to their use in the treatment of (especially cysteine protease, such as UCH-L3- and/or USP-2 dependent) diseases or for the manufacture of pharmaceutical formulations against these diseases, methods of treatment of warm-blooded animals comprising administering the compounds and/or their salts to said animals and pharmaceutical preparations, especially for the treatment of the diseases, comprising said compounds and/or salts.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: April 20, 2010
    Assignee: Novartis AG
    Inventors: Stefanie Flohr, Pascal Furet, Patricia Imbach, Ulrich Hommel, Hans-Ulrich Litshcer, Shirley Gil Parrado, Ulrich Hassiepen, Johann Zimmermann
  • Publication number: 20100044695
    Abstract: Disclosed is an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution. Also disclosed is a compound useful for the fabrication of said organic EL device. The organic electroluminescent device comprises organic layers including a light-emitting layer disposed between an anode and a cathode which are piled one upon another on a substrate and said organic layers comprise a compound represented by general formula (1). A light-emitting layer containing a phosphorescent dopant is suitable for an organic layer comprising a compound represented by general formula (1).
    Type: Application
    Filed: March 24, 2008
    Publication date: February 25, 2010
    Applicant: Nippon Steel Chemical Co., Ltd.
    Inventors: Takahiro Kai, Toshihiro Yamamoto, Masanori Hotta, Junya Ogawa
  • Patent number: 7618968
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: November 17, 2009
    Assignee: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A Jenkins, J Peter Klein, Anil M Kumar, John Tulinsky
  • Patent number: 7608620
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: October 27, 2009
    Assignee: Cell Therapeutics, Inc.
    Inventors: Lynn Bonham, Baoqing Gong, Robert E Finney, David M Hollenback, J Peter Klein, David W Leung, Scott A Shaffer, Norina M Tang, John Tulinsky, Thayer H White
  • Patent number: 7592451
    Abstract: The present invention relates to a compound having the formula where Z is an amine, phenoxy, or thiol-containing group, and Y is an alkyl-containing amine. Methods of producing such compounds and using them to treat patients with diabetes and obesity are also disclosed. The present invention also relates to treating such conditions with GADPH inhibitors and screening compounds useful for treating such conditions by using GADPH inhibitors. Compounds can also be screened for their effectiveness in modulating diabetes and obesity with a C. elegans strain.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: September 22, 2009
    Assignee: New York University
    Inventors: Young-Tae Chang, Fabio Piano
  • Patent number: 7589092
    Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: September 15, 2009
    Assignee: Koronis Pharmaceuticals, Incorporated
    Inventors: Richard Daifuku, Alexander Gall, Dmitri Sergueev, Dina Sologub, Kevin Harris
  • Patent number: 7566712
    Abstract: Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: July 28, 2009
    Assignee: Neurogen Corporation
    Inventors: Rajagopal Bakthavatchalam, Charles A. Blum, Stéphane De Lombaert, Taeyoung Yoon, Xiaozhang Zheng
  • Patent number: 7563792
    Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: July 21, 2009
    Assignee: Jacobus Pharmaceutical Company, Inc.
    Inventors: David P. Jacobus, Guy A. Schiehser, Hong-Ming Shieh, Norman P. Jensen, Jacek Terpinski
  • Patent number: 7501511
    Abstract: The present invention is directed towards a process for resolving a racemic amino compound derived from dihydro-1,3,5-triazines. The invention is also directed towards the enantiomers of amino derivatives of dihydro-1,3,5-triazines and to their use for the preparation of medicaments, in particular for the treatment of diabetes and malaria.
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: March 10, 2009
    Assignee: Merck Patent GmbH
    Inventors: Gérard Moinet, Daniel Cravo, Thierry Passemar
  • Patent number: 7452883
    Abstract: The invention concerns compounds of general formula (I) wherein: R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. The compounds are useful in the treatment of pathologies related to the insulin-resistance syndrome.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: November 18, 2008
    Assignee: Merck Sante
    Inventors: Gerard Moinet, Daniel Cravo, Liliane Doare, Micheline Kergoat, Didier Mesangeau
  • Patent number: 7449575
    Abstract: This invention concerns the compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R1 and R2 are each independently selected from hydrogen; hydroxy; amino; optionally substituted C1-6alkyl; C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; Ar1; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)-aminocarbonyl; dihydro-2(3H)-furanone; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-6alkyl)amino-C1-4alkylidene; R3 is hydrogen, Ar1, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is optionally substituted C1-10alkyl; C3-10alkenyl; C3-10alkynyl; C3-7cycloalkyl; Ar1 is optionally substituted phenyl; for the manufacture of a medicine for the treatment of
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: November 11, 2008
    Assignee: Janssen Pharmaceutica, Inc.
    Inventors: Paul A. J. Janssen, Jan Heeres, Henri E. L. Moereels, Michael Joseph Kukla, Donald W. Ludovici
  • Publication number: 20080194815
    Abstract: The present invention concerns concentrated aqueous solutions of anionic disazo dyes, comprising salts and or the free acids of anionic dyes of the formula and 2-(2-butoxyethoxy) ethanol wherein the substituents are each as defined in claim 1 and the use of these solutions for dyeing and/or printing hydroxyl-containing substrates and for producing inkjet inks.
    Type: Application
    Filed: May 12, 2005
    Publication date: August 14, 2008
    Applicant: CLARIANT INTERNATIONAL LTD.
    Inventors: Jordi Berenguer, Ludwig Hasemann, Joan Bosch, Susana Basolas
  • Publication number: 20080176852
    Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.
    Type: Application
    Filed: June 27, 2007
    Publication date: July 24, 2008
    Inventors: David P. Jacobus, Guy A. Schiehser, Hong-Ming Shieh, Norman P. Jensen, Jacek Terpinski
  • Patent number: 7354921
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: April 8, 2008
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch
  • Patent number: 7335770
    Abstract: The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.
    Type: Grant
    Filed: March 24, 2004
    Date of Patent: February 26, 2008
    Assignee: Reddy U5 Therapeutics, Inc.
    Inventors: Richard T. Timmer, Christopher W. Alexander, Sivaram Pillarisetti, Uday Saxena, Sesha Sridevi Alluri, Velagala Venkata Rama Murali Krishna Reddy, Manojit Pal, Jangalgar Tirupathy Reddy, Koteswar Rao Yeleswarapu, Gaddam Om Reddy, Potlapally Rajender Kumar